Short answer
TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an 8-K current report with the SEC on July 13, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Item 7.01 contains only a Regulation FD non-incorporation disclaimer.
TACTILE SYSTEMS TECHNOLOGY INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Item 7.01 contains only a Regulation FD non-incorporation disclaimer
- No substantive operating, financial, or shareholder-impacting disclosure in the provided text
Item 8.01 · Other Events
- Exclusive VA/DoD distribution rights for MyoSleeve, expanding TCMD’s compression portfolio into earlier-stage chronic swelling treatment
- $3 million upfront payment to ElastiMed, plus minimum purchase obligations and marketing commitments
- Battery-powered, wearable device adds a lower-burden option complementary to traditional pneumatic compression therapy
- FDA 510(k)-cleared and prescription-based, with commercialization leveraging TCMD’s sales, billing, and patient-support infrastructure
Item EX-99.1 · Exhibit EX-99.1
- Exclusive U.S. VA and DoD distribution rights for ElastiMed’s FDA-cleared MyoSleeve wearable compression device
- $3 million upfront payment plus minimum purchase obligations and marketing commitments, creating near-term cash and execution requirements
- MyoSleeve expands Tactile’s portfolio into earlier-stage chronic swelling and mobility-limiting patients
- Existing sales, billing, and patient-support infrastructure could accelerate commercialization and market access
- Designed to complement, not replace, Tactile’s advanced pneumatic compression therapies, potentially broadening patient coverage across disease severity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TACTILE SYSTEMS TECHNOLOGY INC 8-K filings
Get the next TCMD 8-K as it lands
Follow TCMD for push alerts, or ask the research agent what this filing means.